Tert-butyl 3-(2-((2,6-bis(trifluoromethyl)quinolin-4-yl)amino)acetamido)azetidine-1-carboxylate → N-(azetidin-3-yl)-2-((2,6-bis(trifluoromethyl)quinolin-4-yl)amino)acetamide
反応式
[F:1][C:2]([F:34])([F:33])[C:3]1[CH:12]=[C:11]([NH:13][CH2:14][C:15]([NH:17][CH:18]2[CH2:21][N:20](C(OC(C)(C)C)=O)[CH2:19]2)=[O:16])[C:10]2[C:5](=[CH:6][CH:7]=[C:8]([C:29]([F:32])([F:31])[F:30])[CH:9]=2)[N:4]=1>O1CCOCC1>[NH:20]1[CH2:21][CH:18]([NH:17][C:15](=[O:16])[CH2:14][NH:13][C:11]2[C:10]3[C:5](=[CH:6][CH:7]=[C:8]([C:29]([F:31])([F:30])[F:32])[CH:9]=3)[N:4]=[C:3]([C:2]([F:1])([F:33])[F:34])[CH:12]=2)[CH2:19]1参加物
3
実験手順
A solution of tert-butyl 3-(2-((2,6-bis(trifluoromethyl)quinolin-4-yl)amino)acetamido)azetidine-1-carboxylate (291 mg, 1.04 mmol) in dry dioxane (5 mL), prepared in Step C above, was de-protected as described in example to afford the product. ESI-MS (m/z): Calcd. For C16H14F3N4O: 392.11. found: 393 (M+H).
後処理
- customto afford the product